If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

September 12, 2011 | A version of this story appeared in Volume 89, Issue 37

Solutia has agreed to pay $3.4 million to Taiwan’s Aimcore Technology for facilities that can produce conductive film. Solutia says the purchase will help it better serve the Asian mobile-electronics and touch-screen markets with its Flexvue conductive film.

Evonik Industries will enter the functionalized polybutadiene market with the construction of a plant to open in Marl, Germany, in the fall of 2012. The firm will sell hydroxyl-terminated polybutadiene as an auto adhesive and as a sealing compound for insulated glass.

Linde will build what it is calling Europe’s largest electronics-grade fluorine plant at Schüco’s thin-film silicon photovoltaics facility in Großröhrsdorf, Germany. Schüco will use fluorine in place of nitrogen trifluoride as a chamber-cleaning gas.

BASF Canada and Quantiam Technologies have formed a new business called BASF Qtech that will commercialize Quantiam’s catalytic surface coatings for steam cracker furnace tubes. The partners expect to launch a product for ethane-propane cracking this fall.

Evonik Industries says the doubling of the size of its l-lysine plant, housed at Cargill’s Blair, Neb., corn-processing complex, is six months ahead of schedule. The firm now expects to complete the expansion, to 280,000 metric tons per year, by August 2012.

International Flavors & Fragrances will expand its Caplock flavor encapsulation facility in Haverhill, England. Combined with earlier investments, the project will bring spending on the technology at the site to $10 million, IFF says.

Amakem has raised $25 million in a round of venture capital investment. The Belgian firm will use the funds to advance its ophthalmology drug development portfolio and its lead candidate, a glaucoma treatment, to proof of concept.

Merck Serono and F-Star will collaborate on antibody-derived inflammatory disease drugs that are discovered with F-Star’s Modular Antibody Technology. F-Star, based in Vienna, could get payments of as much as $700 million if all goals are met.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.